iTeos Therapeutics, Inc. - ITOS STOCK NEWS

iTeos Therapeutics, a clinical-stage biopharmaceutical company, announced that CEO Michel Detheux will present at the 40th Annual J.P. Morgan Conference on January 11, 2022, at 11:15 a.m. ET. The presentation will focus on the company's advancements in immuno-oncology therapeutics. A live webcast will be accessible on the company's investor website, with a replay available for 30 days post-event. iTeos is developing innovative therapies, including the anti-TIGIT antibody EOS-448 and the adenosine A2A receptor antagonist inupadenant, aimed at enhancing anti-cancer responses.

iTeos Therapeutics (NASDAQ: ITOS) will replace Magellan Health (NASDAQ: MGLN) in the S&P SmallCap 600, effective January 5, 2022. This change coincides with Centene Corp. (NYSE: CNC) acquiring Magellan Health, pending final conditions. The adjustment is significant for iTeos as inclusion in a prominent index like the S&P SmallCap 600 can potentially improve market visibility and investor interest. This strategic move highlights the dynamic shifts within the healthcare sector as companies adapt to evolving market conditions.

iTeos Therapeutics (NASDAQ: ITOS) presented preclinical data for its anti-TIGIT monoclonal antibody, EOS-448, at the ASH Annual Meeting and the TIGIT Therapies Digital Summit. The results demonstrate EOS-448's potential as a single agent and in combination with immunomodulatory drugs in treating multiple myeloma. Evidence highlights its multifaceted mechanism of action, including the activation of immune cells and depletion of immunosuppressive cells. The company is optimistic about progressing clinical trials in 2022 to improve outcomes for patients with advanced cancers.

MPM Capital has appointed Detlev Biniszkiewicz, Ph.D., as a Managing Director and Investment Committee member. His leadership and scientific expertise have contributed significantly to MPM and its portfolio, including launching several companies such as NextPoint Therapeutics. Biniszkiewicz has been with MPM since 2018 and serves on the board of iTeos Therapeutics (NASDAQ: ITOS). MPM Capital is a leading biotech investment firm focused on transforming scientific innovations into impactful therapies.

iTeos Therapeutics (NASDAQ: ITOS) announced significant advancements in its clinical trials for anti-TIGIT monoclonal antibody EOS-448 and inupadenant (EOS-850). The first patients have been dosed in trials combining EOS-448 with pembrolizumab, addressing solid tumors, and starting an expansion for PD-1 resistant melanoma. iTeos closed a $625 million collaboration agreement with GSK, bolstering its cash balance to $899.8 million as of September 30, 2021, enough to support development activities through 2026 while reporting a net income of $69.6 million for Q3 2021.

iTeos Therapeutics (Nasdaq: ITOS) announced a conference call scheduled for November 10, 2021, at 4:30 p.m. ET to discuss its third quarter 2021 financial results and provide a corporate update. The company specializes in developing immuno-oncology therapeutics, focusing on restoring immune responses against cancer. Their pipeline includes EOS-448, an anti-TIGIT antibody, and inupadenant, an adenosine A2A receptor antagonist, which are progressing into clinical trials. Investors can access the call by dialing provided numbers or via a live webcast.

iTeos Therapeutics, a clinical-stage biopharmaceutical company, announced participation in five virtual investor conferences throughout September 2021. Key events include the KBC Securities Life Sciences Conference on September 7 and the Wells Fargo Virtual Healthcare Conference on September 9-10. Additionally, iTeos will present at the Morgan Stanley 19th Annual Global Healthcare Conference from September 9-15, the H.C. Wainwright Annual Global Investment Conference on September 13, and the Cantor Fitzgerald Global Healthcare Conference on September 27. Audio webcasts will be accessible on their website.

iTeos Therapeutics (NASDAQ: ITOS) announced a collaboration with GSK for the co-development of EOS-448, receiving a $625 million upfront payment and potential milestone payments of $1.45 billion. The agreement includes a 40/60 cost-sharing on global development and a 50/50 profit sharing in the U.S. Initial clinical data presented shows promising anti-cancer activity for EOS-448. The company reported a cash balance of $302.9 million as of June 30, 2021, bolstered by the GSK payment, extending its runway into 2026.

iTeos Therapeutics, Inc. (Nasdaq: ITOS) will host a conference call on August 12, 2021, at 8:00 a.m. ET to report its second quarter 2021 financial results and offer a corporate update. The event will be accessible via a pre-registration link and a live audio webcast available on the company's investor relations website. iTeos is focused on immuno-oncology therapeutics with ongoing trials for EOS-448, an anti-TIGIT antibody, and inupadenant, an adenosine A2A receptor antagonist. Preliminary data indicates potential clinical activity and favorable tolerability for both candidates.